Nicotinell Mint 1 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

nicotinell mint 1 mg imeskelytabletti

haleon denmark aps - nicotine bitartrate dihydrate - imeskelytabletti - 1 mg - nikotiini

Nicotinell Fruit 2 mg lääkepurukumi Suomi - suomi - Fimea (Suomen lääkevirasto)

nicotinell fruit 2 mg lääkepurukumi

haleon denmark aps - nicotine polacrilex - lääkepurukumi - 2 mg - nikotiini

Nicotinell Fruit 4 mg lääkepurukumi Suomi - suomi - Fimea (Suomen lääkevirasto)

nicotinell fruit 4 mg lääkepurukumi

haleon denmark aps - nicotine polacrilex - lääkepurukumi - 4 mg - nikotiini

Daivobet 50 / 500 mikrog/g geeli Suomi - suomi - Fimea (Suomen lääkevirasto)

daivobet 50 / 500 mikrog/g geeli

leo pharma a/s - calcipotriol hydrate, betamethasone dipropionate - geeli - 50 / 500 mikrog/g - kalsipotrioli

Enstilar 50 mikrog/g + 0,5 mg/g ihovaahto Suomi - suomi - Fimea (Suomen lääkevirasto)

enstilar 50 mikrog/g + 0,5 mg/g ihovaahto

leo pharma a/s - betamethasone dipropionate, calcipotriol hydrate - ihovaahto - 50 mikrog/g + 0,5 mg/g - kalsipotrioli

Adtralza Euroopan unioni - suomi - EMA (European Medicines Agency)

adtralza

leo pharma a/s - tralokinumab - dermatitis, atopic - muut dermatologiset valmisteet - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Spikevax (previously COVID-19 Vaccine Moderna) Euroopan unioni - suomi - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

AMOSYT 100 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

amosyt 100 mg tabletti

leo - dimenhydrinatum - tabletti - 100 mg - difenhydramiini

AMOSYT-KOFFEIN tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

amosyt-koffein tabletti

leo - dimenhydrinatum,kofeiini - tabletti - difenhydramiini, yhdistelmävalmisteet